<DOC>
	<DOCNO>NCT00787150</DOCNO>
	<brief_summary>To assess effect two dos Apixaban ( 2.5 mg BID 5 mg BID ) versus Warfarin composite endpoint major clinically relevant non-major bleeding treatment period .</brief_summary>
	<brief_title>A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Age â‰¥ 20 year outpatient ( regardless sex ) Patients diagnose nonvalvular atrial fibrillation ( NVAF ) One follow risk stroke . Recent cerebral infarction ( include TIA ) within 4 week week 0 . Subjects suspect serious/hereditary bleeding tendency , disseminate intravascular coagulation syndrome ( DIC ) , congenital platelet dysfunction von Willebrand disease ( suspect family history include ) . Subjects suspect serious/hereditary thrombogenic tendency ( suspect family history include ) require continuation Warfarin therapy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>